

FDB: HIGHEST RATINGS IN KLAS CDS REPORT

Performance Report on Clinical Decision Support

KLAS CDS Report rated FDB the highest in each of the key indicators for *Information Credibility, Relevance of Information, EMR Integration, Influence on Decisions, Standardisation of Care, and Overall Meeting Needs* within the “Drug Database” segment.

On November 28, 2011, KLAS, a highly respected research firm that has been described as a *Consumer Reports* or a *J.D. Power and Associates* for healthcare information technology products, released *Clinical Decision Support 2011: Understanding the Impact*.

This report represents the first effort by KLAS to formally measure and evaluate clinical decision support (CDS) tools and vendors. KLAS surveyed numerous hospital-based executives and clinicians in order to determine CDS tool impact on standardising care, clinical decisions and patient outcomes.


KLAS, whose mission is “to improve healthcare technology delivery by honestly, accurately and impartially measuring vendor performance for

our provider partners,” evaluated seven CDS segments: Drug Databases, Care Plans, Diagnostic Decision Support, Disease Reference, Order Sets, and Surveillance.

The Number One Issue: “Alerts”

“Alerts” were identified as the area requiring the most improvement for the entire “Drug Database” segment of providers. Additionally, two other areas—*Update Process* and *Accuracy*—were identified as needing improvement for competitive “drug databases,” but **not** for FDB. The KLAS report states: “*If vendors can find a way to present their information more usefully within the clinical workflow, drug databases have the potential to be among the most highly impactful CDS tools.*”

Clinical Decision Support 2011: Understanding the Impact, November 2011



FDB's Recent Advances to Address Medication Alert Fatigue

During 2011, FDB instituted a three-pronged approach to address the alert fatigue challenge and has made significant progress to increase the effectiveness of alert management within medication decision-support systems. FDB is committed to continuing to help solve this industry-wide challenge.

Fine-tuning existing content to reduce inappropriate alerts

- Modifying severity levels for drug-drug interaction pairs based on new clinical evidence
- Refining allergy cross-sensitivities
- Increasing the duplicate therapy warning thresholds for clinically reasonable combinations
- Refining drug-disease contraindications to more specific International Classification of diseases (ICD) codes to decrease broad code alerts

Applying new parameters and filters to improve alert effectiveness

- Limiting drug-drug interactions to criteria such as specific dosage forms as clinically determined to be necessary
- Parameter for duplicate therapy warning thresholds

Learn More

The KLAS report *Clinical Decision Support 2011: Understanding the Impact* is available to healthcare providers.

Visit www.KLASresearch.com for more information.

Addressing the Alert Fatigue Challenge



For more information, contact Sales today at 01392 440 100. Or, visit fdbhealth.eu

FDB (First Databank) provides drug knowledge that helps healthcare professionals make precise medication-related decisions. With thousands of customers worldwide, FDB enables our information system developer partners to deliver a wide range of valuable, useful, and differentiated solutions. As the company that virtually launched the medication decision support category, we offer more than three decades of experience in transforming drug knowledge into dynamic, targeted, and effective solutions that improve patient safety and healthcare outcomes. For a complete look at our solutions and services please visit fdbhealth.eu

First Databank, Swallowtail House, Grenadier Road, Exeter Business Park • EX1 3LH • Tel. +44 (0)1392 440 100 • www.fdbhealth.eu
Other Locations: San Francisco • Indianapolis, Indiana • St. Louis, Missouri